246 related articles for article (PubMed ID: 24505487)
1. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Meijers JC; Porte RJ; Lisman T
PLoS One; 2014; 9(2):e88390. PubMed ID: 24505487
[TBL] [Abstract][Full Text] [Related]
2. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Welzel D; Hull R; Fareed J
Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
[TBL] [Abstract][Full Text] [Related]
4. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
[TBL] [Abstract][Full Text] [Related]
5. In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis.
Lisman T; Kleiss S; Patel VC; Fisher C; Adelmeijer J; Bos S; Singanayagam A; Stoy SH; Shawcross DL; Bernal W
Liver Int; 2018 Nov; 38(11):1988-1996. PubMed ID: 29768734
[TBL] [Abstract][Full Text] [Related]
6. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Samama MM; Guinet C; Le Flem L; Ninin E; Debue JM
J Thromb Thrombolysis; 2013 Feb; 35(2):140-6. PubMed ID: 23335022
[TBL] [Abstract][Full Text] [Related]
7. [New anticoagulants].
Godier A; Martin AC; Lakhdari M; Samama CM
Rev Prat; 2011 Nov; 61(9):1239-43. PubMed ID: 22308807
[TBL] [Abstract][Full Text] [Related]
8. [From heparin to apixaban: anticoagulants cut both ways?].
Hartung K; Meyer F; Bock F; Isermann B
Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104
[TBL] [Abstract][Full Text] [Related]
9. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
10. Old versus new anticoagulants: focus on pharmacology.
Benmira S; Banda ZK; Bhattacharya V
Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):120-37. PubMed ID: 20337579
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC; White A; Luettgen J
Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
[TBL] [Abstract][Full Text] [Related]
12. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
13. [Contribution of novel anticoagulants fondaparinux and dabigatran to venous thromboembolism prevention].
Antonijević N; Kanjuh V; Živković I; Jovanović L; Vukčević M; Apostolović M
Srp Arh Celok Lek; 2015; 143(3-4):230-6. PubMed ID: 26012138
[TBL] [Abstract][Full Text] [Related]
14. Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Streif W; Ageno W
Wien Med Wochenschr; 2011 Feb; 161(3-4):73-9. PubMed ID: 21404143
[TBL] [Abstract][Full Text] [Related]
15. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Quinlan DJ; Eriksson BI
Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
17. Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.
Levi M
Thromb Haemost; 2012 Aug; 108(2):201-2. PubMed ID: 22739774
[No Abstract] [Full Text] [Related]
18. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
J Thromb Haemost; 2016 May; 14(5):1043-53. PubMed ID: 26924677
[TBL] [Abstract][Full Text] [Related]
19. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
20. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
